[A25-45] Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2025
Project no.:
A25-45
Commission:
Commission awarded on 28.03.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced clear cell renal cell carcinoma that has progressed following 2 or more lines of therapy that included a PD‑(L)1 inhibitor and at least 2 vascular endothelial growth factor‑targeted therapies
- Patients < 65 years of age for whom everolimus is a suitable individualized treatment: hint of a minor added benefit
- Patients ≥ 65 years of age for whom everolimus is a suitable individualized treatment: hint of a considerable added benefit
- Patients for whom everolimus is not a suitable individualized treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-45
| Project no. | Title | Status |
|---|---|---|
| A25-44 | Belzutifan (Von-Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |